Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism
Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and secondary prevention of venous thromboembolism (VTE). The optimal duration of anticoagulation has been an active area of clinical investigation for patients undergoing orthopedic surgeries and those diagn...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmacy practice 2010-08, Vol.23 (4), p.313-323 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 323 |
|---|---|
| container_issue | 4 |
| container_start_page | 313 |
| container_title | Journal of pharmacy practice |
| container_volume | 23 |
| creator | Conway, Susan E. Marcy, Todd R. |
| description | Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and secondary prevention of venous thromboembolism (VTE). The optimal duration of anticoagulation has been an active area of clinical investigation for patients undergoing orthopedic surgeries and those diagnosed with a first episode of unprovoked VTE. Practice guidelines, VTE incidence, clinical predictors/mediators, and clinical trial evidence is reviewed to help pharmacists and other health care providers make an informed, patient-specific decision on the optimal duration of anticoagulation therapy. Extended anticoagulation up to 5 weeks following orthopedic surgery for primary VTE prevention and indefinitely following a first episode of unprovoked VTE for secondary VTE prevention should be considered only if the risk of bleeding is not high and the cost and burden of anticoagulation is acceptable to the patient. The optimal duration of anticoagulation therapy for primary or secondary prevention of VTE should include the health care provider and patient making a decision based on evaluation of individual benefits, risks, and preferences. |
| doi_str_mv | 10.1177/0897190010366930 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877592192</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0897190010366930</sage_id><sourcerecordid>877592192</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-d425a5fd66a0b861e7cfc979238f618b2758516c326d0df3266cbb72db20fed23</originalsourceid><addsrcrecordid>eNqNkc1Lw0AQxRdRbK3ePUlunqI7u93d5CilfkChBavXkGRnNSXJ1t1E7H9vQqoHQfQwDMP83mOYR8g50CsApa5pFCuIKQXKpYw5PSBjEBxCiLk6JON-Hfb7ETnxfkMpgylnx2TEQFAVcRiT5fyjwVqjDtav6NLtLjDWBStXVKnbBWmtg0fMba37aeXwHeumsHVgTfCMtW19J3O2yix2VRa-OiVHJi09nu37hDzdztez-3CxvHuY3SzCnINoQj1lIhVGS5nSLJKAKjd5rGLGIyMhypgSkQCZcyY11aZrMs8yxXTGqEHN-IRcDr5bZ99a9E1SFT7Hskxr7M5KIqVEzCD-JwlKwt-k5FPGIkE7kg5k7qz3Dk2yHT6WAE36ZJKfyXSSi715m1WovwVfUXRAOAA-fcFkY1tXdw_83fATYmeUwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>863422850</pqid></control><display><type>article</type><title>Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Conway, Susan E. ; Marcy, Todd R.</creator><creatorcontrib>Conway, Susan E. ; Marcy, Todd R.</creatorcontrib><description>Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and secondary prevention of venous thromboembolism (VTE). The optimal duration of anticoagulation has been an active area of clinical investigation for patients undergoing orthopedic surgeries and those diagnosed with a first episode of unprovoked VTE. Practice guidelines, VTE incidence, clinical predictors/mediators, and clinical trial evidence is reviewed to help pharmacists and other health care providers make an informed, patient-specific decision on the optimal duration of anticoagulation therapy. Extended anticoagulation up to 5 weeks following orthopedic surgery for primary VTE prevention and indefinitely following a first episode of unprovoked VTE for secondary VTE prevention should be considered only if the risk of bleeding is not high and the cost and burden of anticoagulation is acceptable to the patient. The optimal duration of anticoagulation therapy for primary or secondary prevention of VTE should include the health care provider and patient making a decision based on evaluation of individual benefits, risks, and preferences.</description><identifier>ISSN: 0897-1900</identifier><identifier>EISSN: 1531-1937</identifier><identifier>DOI: 10.1177/0897190010366930</identifier><identifier>PMID: 21507831</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Heparin, Low-Molecular-Weight - adverse effects ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Practice Guidelines as Topic ; Secondary Prevention - methods ; Time Factors ; Venous Thromboembolism - drug therapy ; Venous Thromboembolism - epidemiology ; Venous Thromboembolism - metabolism ; Venous Thromboembolism - prevention & control</subject><ispartof>Journal of pharmacy practice, 2010-08, Vol.23 (4), p.313-323</ispartof><rights>The Author(s) 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c315t-d425a5fd66a0b861e7cfc979238f618b2758516c326d0df3266cbb72db20fed23</citedby><cites>FETCH-LOGICAL-c315t-d425a5fd66a0b861e7cfc979238f618b2758516c326d0df3266cbb72db20fed23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0897190010366930$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0897190010366930$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21507831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conway, Susan E.</creatorcontrib><creatorcontrib>Marcy, Todd R.</creatorcontrib><title>Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism</title><title>Journal of pharmacy practice</title><addtitle>J Pharm Pract</addtitle><description>Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and secondary prevention of venous thromboembolism (VTE). The optimal duration of anticoagulation has been an active area of clinical investigation for patients undergoing orthopedic surgeries and those diagnosed with a first episode of unprovoked VTE. Practice guidelines, VTE incidence, clinical predictors/mediators, and clinical trial evidence is reviewed to help pharmacists and other health care providers make an informed, patient-specific decision on the optimal duration of anticoagulation therapy. Extended anticoagulation up to 5 weeks following orthopedic surgery for primary VTE prevention and indefinitely following a first episode of unprovoked VTE for secondary VTE prevention should be considered only if the risk of bleeding is not high and the cost and burden of anticoagulation is acceptable to the patient. The optimal duration of anticoagulation therapy for primary or secondary prevention of VTE should include the health care provider and patient making a decision based on evaluation of individual benefits, risks, and preferences.</description><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Heparin, Low-Molecular-Weight - adverse effects</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Practice Guidelines as Topic</subject><subject>Secondary Prevention - methods</subject><subject>Time Factors</subject><subject>Venous Thromboembolism - drug therapy</subject><subject>Venous Thromboembolism - epidemiology</subject><subject>Venous Thromboembolism - metabolism</subject><subject>Venous Thromboembolism - prevention & control</subject><issn>0897-1900</issn><issn>1531-1937</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1Lw0AQxRdRbK3ePUlunqI7u93d5CilfkChBavXkGRnNSXJ1t1E7H9vQqoHQfQwDMP83mOYR8g50CsApa5pFCuIKQXKpYw5PSBjEBxCiLk6JON-Hfb7ETnxfkMpgylnx2TEQFAVcRiT5fyjwVqjDtav6NLtLjDWBStXVKnbBWmtg0fMba37aeXwHeumsHVgTfCMtW19J3O2yix2VRa-OiVHJi09nu37hDzdztez-3CxvHuY3SzCnINoQj1lIhVGS5nSLJKAKjd5rGLGIyMhypgSkQCZcyY11aZrMs8yxXTGqEHN-IRcDr5bZ99a9E1SFT7Hskxr7M5KIqVEzCD-JwlKwt-k5FPGIkE7kg5k7qz3Dk2yHT6WAE36ZJKfyXSSi715m1WovwVfUXRAOAA-fcFkY1tXdw_83fATYmeUwA</recordid><startdate>201008</startdate><enddate>201008</enddate><creator>Conway, Susan E.</creator><creator>Marcy, Todd R.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>201008</creationdate><title>Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism</title><author>Conway, Susan E. ; Marcy, Todd R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-d425a5fd66a0b861e7cfc979238f618b2758516c326d0df3266cbb72db20fed23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Heparin, Low-Molecular-Weight - adverse effects</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Practice Guidelines as Topic</topic><topic>Secondary Prevention - methods</topic><topic>Time Factors</topic><topic>Venous Thromboembolism - drug therapy</topic><topic>Venous Thromboembolism - epidemiology</topic><topic>Venous Thromboembolism - metabolism</topic><topic>Venous Thromboembolism - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conway, Susan E.</creatorcontrib><creatorcontrib>Marcy, Todd R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conway, Susan E.</au><au>Marcy, Todd R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism</atitle><jtitle>Journal of pharmacy practice</jtitle><addtitle>J Pharm Pract</addtitle><date>2010-08</date><risdate>2010</risdate><volume>23</volume><issue>4</issue><spage>313</spage><epage>323</epage><pages>313-323</pages><issn>0897-1900</issn><eissn>1531-1937</eissn><abstract>Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and secondary prevention of venous thromboembolism (VTE). The optimal duration of anticoagulation has been an active area of clinical investigation for patients undergoing orthopedic surgeries and those diagnosed with a first episode of unprovoked VTE. Practice guidelines, VTE incidence, clinical predictors/mediators, and clinical trial evidence is reviewed to help pharmacists and other health care providers make an informed, patient-specific decision on the optimal duration of anticoagulation therapy. Extended anticoagulation up to 5 weeks following orthopedic surgery for primary VTE prevention and indefinitely following a first episode of unprovoked VTE for secondary VTE prevention should be considered only if the risk of bleeding is not high and the cost and burden of anticoagulation is acceptable to the patient. The optimal duration of anticoagulation therapy for primary or secondary prevention of VTE should include the health care provider and patient making a decision based on evaluation of individual benefits, risks, and preferences.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>21507831</pmid><doi>10.1177/0897190010366930</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0897-1900 |
| ispartof | Journal of pharmacy practice, 2010-08, Vol.23 (4), p.313-323 |
| issn | 0897-1900 1531-1937 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_877592192 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Anticoagulants - adverse effects Anticoagulants - therapeutic use Heparin, Low-Molecular-Weight - adverse effects Heparin, Low-Molecular-Weight - therapeutic use Humans Practice Guidelines as Topic Secondary Prevention - methods Time Factors Venous Thromboembolism - drug therapy Venous Thromboembolism - epidemiology Venous Thromboembolism - metabolism Venous Thromboembolism - prevention & control |
| title | Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A12%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extended%20Therapy%20for%20Primary%20and%20Secondary%20Prevention%20of%20Venous%20Thromboembolism&rft.jtitle=Journal%20of%20pharmacy%20practice&rft.au=Conway,%20Susan%20E.&rft.date=2010-08&rft.volume=23&rft.issue=4&rft.spage=313&rft.epage=323&rft.pages=313-323&rft.issn=0897-1900&rft.eissn=1531-1937&rft_id=info:doi/10.1177/0897190010366930&rft_dat=%3Cproquest_cross%3E877592192%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=863422850&rft_id=info:pmid/21507831&rft_sage_id=10.1177_0897190010366930&rfr_iscdi=true |